Human TNF-alpha Protein, Research Grade

Research use only
This product is designed for academic and scientific research institutions.
Cat. No. / Size
Price
Availability
Qty
TNA-H5213-20ug
$69.00
In Stock - Delivery in 1-2 business days
TNA-H5213-100ug
$199.00
In Stock - Delivery in 1-2 business days
TNA-H5213-1mg (500ug X 2)
$1,299.00
In Stock - Delivery in 2 weeks
TNA-H5213
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Features and Advantages
  • Native Conformation: Native sequences, tag-free and natural function.
  • Reliable Activity: Biological activity calibrated against WHO/NIBSC standards.
  • Stringent Quality Control: Protein content, purity, and cell-based bioactivity testing for each batch.
  • Lowest Endotoxin level (<0.01 EU/ug).
  • Safety Assurance: Sterile filtration through 0.2 μm membrane.
  • AOF: Animal origin-free raw materials throughout the production process.
Synonyms

DIF, TNF-alpha, TNFA, TNFSF2, cachexin, cachectin, TNFα

Source

Human TNF-alpha Protein, Research Grade (TNA-H5213) is expressed from human 293 cells (HEK293). It contains AA Val 77 - Leu 233 (Accession # P01375-1).

Predicted N-terminus: Val 77

Molecular Characterization

This protein carries no "tag".

The protein has a calculated MW of 17.4 kDa. The protein migrates as 17 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 0.01 EU per μg by the LAL method / rFC method.

Purity

>95% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 24 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
Quality Description

ACRO's Research-grade products are suitable for a wide range of cell culture applications, particularly for research use in academic institutions. These products are sterilized by filtration, followed by lyophilization where applicable. Typical specifications include endotoxin levels of <0.01 EU/μg and purities >95%. Biological activity is calibrated against WHO/NIBSC standards when available.
ACRO's Premium-grade (Pre-GMP) products are characterized by their high quality and enhanced safety profiles, making them ideal for early-stage discovery and manufacturing processes in cell therapy companies. A key advantage is their seamless transition to corresponding GMP-grade versions. Biological activity is calibrated against WHO/NIBSC standards when available. Typical specifications include endotoxin levels of <0.01 EU/μg and purities >95%. In addition, rigorous testing is conducted to ensure the absence of mycoplasma, HCD, and HCP, thereby guaranteeing product safety.

Background

Tumor necrosis factor alpha (TNFα) is a cytokine produced primarily by monocytes and macrophages. It is found in synovial cells and macrophages in the tissues.The primary role of TNFα is in the regulation of immune cells. TNFα is able to induce apoptotic cell death, to induce inflammation, and to inhibit tumorigenesis and viral replication. Dysregulation of TNFα production has been implicated in a variety of human diseases, including major depression, Alzheimer's disease and cancer. Recombinant TNFα is used as an immunostimulant under the INN tasonermin. TNFα can be produced ectopically in the setting of malignancy and parallels parathyroid hormone both in causing secondary hypercalcemia and in the cancers with which excessive production is associated.